MedTrace Logo

Itopride in Feeding Intolerance of Critically-ill Patients Receiving Enteral Nutrition

NCT03698292 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-10-05

No results posted yet for this study

Summary

The current study will compare the effectiveness as well as the safety of Itopride against metoclopramide as the first line treatment for feeding intolerance in critically ill patients.

Conditions

  • Critically-ill Patients

Interventions

DRUG

Itopride

Prokinetic Drug

DRUG

Metoclopramide 10mg

Prokinetic Drug

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2019-06-30
Completion
2019-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698292 on ClinicalTrials.gov